38449-49-9

Usage

InChI:InChI=1/C7H9NO2S2/c1-2-10-6(9)3-5-4-12-7(11)8-5/h4H,2-3H2,1H3,(H,8,11)

Upstream product

• 89910-38-3 (4-hydroxy-2-thioxo-thiazolidin-4-yl)-acetic acid ethyl ester 
• 638-07-3 ethyl (2-chloroaceto)acetate 
• 513-74-6 ammonium dithiocarbamate 
• 41665-64-9 bis-(4-ethoxycarbonylmethyl-thiazol-2-yl)-disulfide 
• 16687-42-6 ammonium thiocarbamate 

Downstream Products

• 36365-79-4 (2-thioxo-2,3-dihydro-thiazol-4-yl)-acetic acid 
• 123999-60-0 6,7-dihydro-6-oxo-4-phenyl-5H-thiazolo<4,3,2-d,e>thiazolo<3,4-a>pyrimidinium benzenesulfonate 
• 36365-79-4 2-mercapto-1,3-thiazol-4-yl-acetic acid 
• 879399-82-3 (2S)-[4-(carboxymethyl)thiazol-2-ylthio]-N-{[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}acetamide 
• 1002092-12-7 (2S)-[4-(carboxymethyl)thiazol-2-ylthio]-N-{[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}acetamide hydrobromide 
• 194928-82-0 (6R,7R)-3-(4-Carbamoylmethyl-thiazol-2-ylsulfanyl)-8-oxo-7-phenylacetylamino-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid 

Relevant academic research and scientific papers

Thiazole- and imidazole-containing peptidomimetic inhibitors of protein farnesyltransferase

Mimetics of the C-terminal CAAX tetrapeptide of Ras protein were designed replacing internal dipeptide AA with 4-amino-2-phenylbenzoic acid and cysteine (C) with 2-amino-4-thiazolyl-, 2-mercapto-4-thiazolyl-, 2-mercapto-4-imidazolyl- and 2-methylmercapto-4-thiazolyl-acetic or propionic acid. The compound in which C is replaced by 2-amino-4-thiazolylacetic acid inhibited FTase activity in the low nanomolar range and showed antiproliferative effect on rat aortic smooth muscle cells interfering with Ras farnesylation. On the basis of these results, 2-aminothiazole can be considered as an alternative to heterocycles, such as pyridine and imidazole, normally used in FTase inhibitors designed as non-thiol CAAX mimetics.

CARBOXYLIC ACID DERIVATIVE CONTAINING THIAZOLE RING AND PHARMACEUTICAL USE THEREOF

According to the present invention, a compound represented by the following formula (I) having a superior PPARα, agonist action and concurrently showing a hypolipidemic action can be provided, and further, a compound useful as a synthetic intermediate for the compound can be provided.

MORPHOLINE COMPOUND

A compound represented by the formula (1) wherein ring A is aryl optionally having substituent(s) and the like; ring B is arylene optionally having substituent(s) and the like; m=0-2; n=1-5; X is a bond and the like; Y is a bond and the like; and Z is hydrogen atom and the like or a pharmaceutically acceptable salt thereof, and a hydrate or solvate thereof have affinity for CCR3, and can be pharmaceutical products for the treatment and/or prophylaxis of immune or inflammatory diseases.

Studies on anti-Helicobacter pylori agents. Part 3: A novel, efficacious cephem derivative, FR193879

The synthesis, therapeutic efficacy against H. pylori, and preliminary safety of the novel cephem derivative, FR193879 (8a) are described. Compound 8a having a (4-carbamoylmethylthiazol-2-yl)thio moiety at the 3-position and a phenylacetamido at the 7-position was found to have good safety showing a nontoxic dose of 100mg/kg in dogs in a 4-week repeat dose toxicity study and extremely potent therapeutic efficacy against H. pylori, showing 30 times superior activity compared to AMPC, and did not display cross-resistance with CAM or MNZ.

REDUCTIVE CLEAVAGE OF SYMMETRICAL DISULFIDES WITH HYDRAZINES

An efficient method for the reductive cleavage of symmetrical disulfides with hydrazines is described.